Mission Pharmacal Company recently acquired the assets of ProSolus Pharmaceuticals headquartered in Miami, FL. Now a wholly owned subsidiary of Mission, ProSolus Inc., offers expertise in the development and manufacturing of sophisticated and convenient transdermal—through the skin—drug delivery products to treat a variety of health conditions.

“ProSolus is the new jewel in Mission’s crown as a manufacturing supplier,” said Pete Valko, chief operating officer, ProSolus Inc., who is adding this to his responsibilities as chief operating officer of BioComp Pharma. “To expand Mission’s offerings, ProSolus brings high-barrier-to-entry transdermal solutions and a top-notch manufacturing facility with its own research and development arms. Mission’s goal is to deliver this exceptional science and skill into customers’ hands through innovative and convenient products.”

ProSolus will operate with former ProSolus chief executive officer Juan Mantelle continuing in executive leadership to oversee research and development as chief scientific officer. ProSolus enables Mission to offer the latest transdermal patches in a wide variety of therapeutic categories.

ProSolus will complement and work in tandem with the Mission family of companies. This includes wholly owned subsidiaries BioComp Pharma, a generic drug company formed in 2009, and Alamo Pharma Services, a specialized contract sales company founded in 2011.

“Juan Mantelle and the ProSolus team excel in the design aspects of transdermal products. It’s really an art more than a science,” said Terry Herring, president, commercial operations, Mission Pharmacal. “They have significantly improved the wearability of transdermal patches, creating more desirable, smaller sizes that stay in place while working effectively. This design strength combined with state-of-the-art manufacturing capabilities gives us vast potential to quickly deliver patient-friendly transdermal solutions.”